We interviewed five private firms, one at a time, to explore and characterize their views on market barriers to the development of cocaine abuse pharmacotherapies and on the readiness of the science base in developing such medications. One of the companies was a large pharmaceutical company; one was a large pharmaceutical company with a strong CNS focus; one was a small biotechnology company with a substance abuse pharmacotherapy in its portfolio; and two were venture capital firms that had investments in health care and biotechnology.
Information gathered from these interviews appears in the Market Barriers section of the report. Appendix E includes a list of selection criteria of the private firms interviewed and a detailed discussion guide that served as our interview protocol.
The next section of the report presents the main findings from our study. Our findings are organized along the following dimensions:
- Market analysis for a prospective cocaine medication
- Scenarios of company decisionmaking
- Case studies of selected pharmacotherapies
- Market barriers to cocaine pharmacotherapy development.